SEC Form 4 · accession 0000947871-17-000210
GLAUKOS Corp · GKOS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Samuel D Isaly
Director
ORBIMED ADVISORS LLC
Director
OrbiMed Capital GP III LLC
Director
Period of report
Mar 10, 2017
Accepted (ET)
Mar 14, 2017 · 7:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001192448
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.01 per shareF1,F5,F7 | Mar 10, 2017 | S | 96,113 | $45.98 | D | 2,008,071 | I | See Footnotes |
| Common Stock, par value $0.01 per shareF1,F6,F7 | Mar 10, 2017 | S | 915 | $45.98 | D | 19,129 | I | See Footnotes |
| Common Stock, par value $0.01 per shareF2,F5,F7 | Mar 13, 2017 | S | 208,712 | $45.30 | D | 1,799,359 | I | See Footnotes |
| Common Stock, par value $0.01 per shareF2,F6,F7 | Mar 13, 2017 | S | 1,998 | $45.30 | D | 17,141 | I | See Footnotes |
| Common Stock, par value $0.01 per shareF3,F5,F7 | Mar 13, 2017 | S | 693 | $46.13 | D | 1,798,666 | I | See Footnotes |
| Common Stock, par value $0.01 per shareF3,F6,F7 | Mar 13, 2017 | S | 7 | $46.13 | D | 17,134 | I | See Footnotes |
| Common Stock, par value $0.01 per shareF4,F5,F7 | Mar 14, 2017 | S | 73,401 | $44.54 | D | 1,725,265 | I | See Footnotes |
| Common Stock, par value $0.01 per shareF4,F6,F7 | Mar 14, 2017 | S | 699 | $44.54 | D | 16,435 | I | See Footnotes |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock ("Shares") were sold in multiple transactions at prices ranging from $45.80 to $46.31 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission (the "SEC") full information regarding the Shares purchased at each separate price within the range set forth in this footnote.
- F2The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $45.00 to $45.87 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares sold at each separate price within the range set forth in this footnote.
- F3The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $46.04 to $46.23 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares sold at each separate price within the range set forth in this footnote.
- F4The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $44.31 to $44.69 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares sold at each separate price within the range set forth in this footnote.
- F5These shares are held of record by OrbiMed Private Investments III, LP ("OPI III"). OrbiMed Capital GP III LLC ("GP III") is the general partner of OPI III, and OrbiMed Advisors LLC ("Advisors") is the managing member of GP III. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships, GP III, Advisors and Isaly may be deemed to have voting and investment power over the securities held by OPI III and as a result may be deemed to have beneficial ownership over such securities.
- F6These shares are held of record by OrbiMed Associates III, LP ("Associates III"). Advisors is the general partner of Associates III. Isaly is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships, Advisors and Isaly may be deemed to have voting and investment power over the securities held by Associates III and as a result may be deemed to have beneficial ownership over such securities.
- F7This report on Form 4 is jointly filed by GP III, Advisors, and Isaly. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Jonathan T. Silverstein, a member of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.